AL008 SIRP-alpha – Oncology

AL008 is a novel immuno-oncology antibody aimed at activating the innate immune system. AL008 works through a unique dual mechanism: it targets the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system, to relieve immune suppression, while also engaging Fc gamma, an activating receptor to promote immune-stimulatory pathways that drive anti-tumor immunity. 

AL008 is being developed in China by Innovent.